Clinical Trials Conditions Microdosing Presentation 
Cannabis Law Report
DECEMBER 2, 2021
IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.
Veriheal
MARCH 20, 2023
Using psilocybin in small doses, or microdosing, has been shown to aid in the treatment of various mental health issues, including anxiety, depression, PTSD, and obsessive-compulsive disorder. Florida Florida presented two bills (SB 348 and HB 193). Minnesota Rep. Missouri Rep. Texas This year, Texas Gov.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Cannigma
JUNE 24, 2021
While many health conditions can be treated with more traditional pharmaceuticals, plant-based products may be a safer and healthier option – or at least a safe health supplement. These natural alternatives may also be effective as part of a daily “microdosing” regiment. Part of a natural, alternative lifestyle.
Cannabis Law Report
SEPTEMBER 10, 2019
Forbes reported on Hopkins researchers’ recommendation that, if psilocybin should clear Phase III clinical trials, the FDA should reclassify it from a Schedule I to a Schedule IV drug. Garcia-Romeu Comments on Recent Study of Psychedelic Microdosing in Rats. Psilocybin in the Treatment of Mood and Substance Use Disorders.
CannaMD
OCTOBER 7, 2019
Besides going against all the classic “munchies/stoner” stereotypes, this finding is especially puzzling as cannabis is often used to increase weight gain in patients with medical conditions such as HIV/AIDS and cancer. In exploring marijuana’s role in weight loss, the present theory specifically highlights the importance of THC.
Expert insights. Personalized for you.
52 
Let's personalize your content